Additionally, the assessment of insulin-like growth factor 1 (IGF-1) is recommended to test for acromegaly, and plasma growth hormone releasing hormone (GHRH) testing is advised to rule out neuroendocrine tumours, while keeping in mind that these tests can be adversely affected by the oral intake of oestrogen supplements [29]. The gene discussed is GHRH; the disease is neuroendocrine neoplasm.